



JCOG Rec'd PCTO 29 SEP 2005

PCT  
#6

Docket No.: A0345.0008  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Hamed Aissaoui, et al.

Application No.: 10/528,043

Confirmation No.: 1015

Filed: September 12, 2003

Art Unit: (to be assigned)

For: I-PYRADIN-4-YL-UREA DERIVATIVES

Examiner: (to be assigned)

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR  
PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES**

United States Patent and Trademark Office  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Commissioner:

In a recent USPTO Notification, a copy of which is enclosed, it is stated that:

This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821 (c).

In response, applicants respectfully submit that the specification does not contain any amino or nucleotide sequence. Therefore, applicants believe that no sequence listing is necessary.

Respectfully submitted,

Dated: September 29, 2005

By \_\_\_\_\_

Charles E. Miller

Reg. No. 24,576

DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP

1177 Avenue of the Americas

New York, New York 10036-2714

(212) 835-1400

Attorney for Applicant

Enclosure



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/528,043	FIRST NAMED APPLICANT Hamed Aissaoui	ATTY. DOCKET NO. A0345.0008
INTERNATIONAL APPLICATION NO. PCT/EP03/10154		
I.A. FILING DATE 09/12/2003		PRIORITY DATE 09/17/2002

32172  
 DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP  
 1177 AVENUE OF THE AMERICAS (6TH AVENUE)  
 41 ST FL.  
 NEW YORK, NY 10036-2714

**RECEIVED**  
 AUG 19 2005  
 DICKSTEIN SHAPIRO

CONFIRMATION NO. 1015  
 371 FORMALITIES LETTER  
 \*OC000000016766592\*  
 \*OC000000016766592\*

Date Mailed: 08/15/2005

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

DSMO FILE NO. A0345.0008

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

C/L: OCT. 15, 2005

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

ENTERED BY: [Signature]

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

ATTY: CEM/IV/FORM

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/528,043	PCT/EP03/10154	A0345.0008

FORM PCT/DO/EO/922 (371 Formalities Notice)